Overview

Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of drugs as a possible treatment for metastatic colorectal cancer characterized by BRAF V600E mutation. The names of the study drugs involved in this study are: - Dabrafenib - Trametinib - PDR001
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Novartis
Stand Up To Cancer
Treatments:
Dabrafenib
Spartalizumab
Trametinib